The recently launched system can measure the concentration and size of extracellular vesicles as small as 50 nanometers and requires no sample preparation.
In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.
The company beat Wall Street expectations on the top and bottom line, and adjusted its guidance for the year upward reflecting the strength of the quarter.
A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.
The South Korean companies have also agreed to work together on the development of exosome-based biomedical products including diagnostics and therapeutics.
The firm will work with investigators from the University of North Carolina at Chapel Hill and the University of Virginia to validate its AIR system in CRISPR workflows.
Based on sequences for hundreds of E. coli ST131 lineage isolates, researchers propose a model that involves negative frequency-dependent selection on accessory parts of the genome.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
Idylla molecular testing instruments will be placed at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.
The company posted revenues of $513.9 million for the quarter compared to $530.7 million in Q1 2018, below the average Wall Street estimate of $545.3 million.
With the approval of its ThyraMIR diagnostic assay, the firm said that physicians will have access to its thyroid product suite across several specimen types.
LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.
Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The test is based on RNA sequencing and is used to differentiate between idiopathic pulmonary fibrosis and other lung diseases in order to avoid surgery.
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.
A team compared expression in duodenum samples from active celiac cases, cases in remission, and unaffected controls, identifying active disease-related expression shifts.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
